LinYHWuVCTsaiIJet al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345-351.
3.
WuVCWangYTWangCYet al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with endstage renal disease. Clin Infect Dis. 2006;42:66-72.
4.
ChenCGuoDHCaoXet al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73:195-206.
5.
HanaiYMatsuoKOgawaMet al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22:536-542.
6.
NukuiYHatakeyamaSOkamotoKet al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128-2133.
7.
ZhangYMYuWZhouNet al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015;14:287-292.
8.
AttassiKHershberberEAlamRZervosMJ.Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695-698.
9.
ZhangZLiangZLiHChenLSheD.Comparative evaluation of thrombocytopenia in adult patients receiving linezolid or glycopeptides in a respiratory intensive care unit. Exp Ther Med. 2014;7:501-507.